跳转至内容
Merck
CN
所有图片(1)

主要文件

查看所有文档

安全信息

V-902

Supelco

Vardenafil dihydrochloride solution

1.0 mg/mL in methanol (as free base), ampule of 1 mL, certified reference material, Cerilliant®

登录查看公司和协议定价
所有图片(1)

About This Item

经验公式（希尔记法）:
C23H32N6O4S·2HCl
CAS号:
224785-90-4
分子量:
561.52
EC 号:
200-659-6
MDL编号:
MFCD04972607
UNSPSC代码:
41116107
PubChem化学物质编号:
329830239
NACRES:
NA.24

等级

certified reference material

质量水平

300

表单

liquid

特点

Snap-N-Spike®/Snap-N-Shoot®

包装

ampule of 1 mL

制造商/商品名称

Cerilliant®

浓度

1.0 mg/mL in methanol (as free base)

技术

gas chromatography (GC): suitable
liquid chromatography (LC): suitable

应用

pharmaceutical (small molecule)

包装形式

single component solution

储存温度

−20°C

SMILES字符串

O=C(C1=C(C)N=C(CCC)N1N2)N=C2C3=CC(S(=O)(N4CCN(CC)CC4)=O)=CC=C3OCC.Cl.Cl

InChI

1S/C23H32N6O4S.2ClH/c1-5-8-20-24-16(4)21-23(30)25-22(26-29(20)21)18-15-17(9-10-19(18)33-7-3)34(31,32)28-13-11-27(6-2)12-14-28;;/h9-10,15H,5-8,11-14H2,1-4H3,(H,25,26,30);2*1H

InChI key

NOIHTGOGFDFCBN-UHFFFAOYSA-N

基因信息

human ... PDE5A(8654)

相关类别

一般描述

Vardenafil, a phosphodiesterase inhibitor, is used to treat erectile dysfunction. This Snap-N-Spike® reference solution is applicable for use in urine drug testing, clinical toxicology or forensic analysis by LC-MS/MS or GC/MS. Vardenafil is sold under the trade names Levitra® and Staxyn®.

法律信息

CERILLIANT is a registered trademark of Merck KGaA, Darmstadt, Germany
Levitra is a registered trademark of Bayer Aktiengesellschaft
Snap-N-Shoot is a registered trademark of Cerilliant Corporation
Snap-N-Spike is a registered trademark of Merck KGaA, Darmstadt, Germany
Staxyn is a registered trademark of Bayer Aktiengesellschaft

警示用语：

Danger

危险分类

Acute Tox. 3 Dermal - Acute Tox. 3 Inhalation - Acute Tox. 3 Oral - Flam. Liq. 2 - STOT SE 1

靶器官

Eyes,Central nervous system

储存分类代码

3 - Flammable liquids

WGK

WGK 2

闪点(°F)

49.5 °F - closed cup

闪点(°C)

9.7 °C - closed cup

法规信息

危险化学品

分析证书(COA)

输入产品批号来搜索 分析证书(COA) 。批号可以在产品标签上"批“ （Lot或Batch）字后找到。

已有该产品？

在文件库中查找您最近购买产品的文档。

访问文档库

B Henriet et al.
Revue medicale de Bruxelles, 33(3), 146-152 (2012-08-16)
Recent societal evolutions have enabled more and more men to talk about erectile dysfunction (ED). There is a strong association between ED and cardiovascular disease and ED should now be considered as an early clinical evidence of vascular disorder. Inhibitors
Valter Javaroni et al.
Urology, 80(4), 858-864 (2012-08-28)
To evaluate whether the response to on-demand vardenafil could be improved by its daily usage in hypertensive men with erectile dysfunction (ED) who previously did not answer to on-demand regime. Our main efficacy criterion was per patient percentage of positive
S I Gamidov et al.
Urologiia (Moscow, Russia : 1999), (3)(3), 102-104 (2013-08-31)
Due to high efficiency, prompt action and low incidence of side effects, phosphodiesterase type 5 inhibitors are the drugs of first choice in the treatment of erectile dysfunction (ED). One of the most widely used drugs in this group currently
Christoph Zenzmaier et al.
Endocrinology, 153(11), 5546-5555 (2012-09-06)
Phosphodiesterase type 5 (PDE5) inhibitors have been demonstrated to improve lower urinary tract symptoms secondary to benign prostatic hyperplasia (BPH). Because BPH is primarily driven by fibroblast-to-myofibroblast trans-differentiation, this study aimed to evaluate the potential of the PDE5 inhibitor vardenafil
[New Levitra in the treatment of erectile dysfunction].
A L Vertkin et al.
Urologiia (Moscow, Russia : 1999), (6)(6), 100-102 (2013-02-06)
查看所有相关文献

我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.

联系技术服务部门